HIGHLIGHTS
- who: Celimene Galiger from the Children`s Hospital of Los Angeles, United States University of Catania, Italy have published the article: PPP2CA Is a Novel Therapeutic Target in Neuroblastoma Cells That Can Be Activated by the SET Inhibitor OP449, in the Journal: (JOURNAL)
- future: Future investigations are warranted to assess the efficacy of OP449 against NB in_vivo.
SUMMARY
Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. Compared with several other PP2A-reactivating drugs (PADs), the novel SET antagonist OP449 has been shown to be particularly effective and devoid . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.